Last updated: August 30, 2026
Etonogestrel and ethinyl estradiol vaginal rings are mature combination contraceptive products with limited remaining composition-of-matter protection in the United States. The main commercial opportunity is a lower-cost generic or private-label ring that matches the reference product’s drug-release profile, dimensions, mechanical properties, packaging, and patient usability. Excipient selection is commercially important because the ring is a controlled-release drug-device-like dosage form, even though FDA regulates it as a drug product.
The reference product, NuvaRing, contains 11.7 mg of etonogestrel and 2.7 mg of ethinyl estradiol. It releases approximately 0.120 mg of etonogestrel and 0.015 mg of ethinyl estradiol per day over three weeks (FDA, 2021a). The principal inactive materials are ethylene-vinyl acetate copolymers and magnesium stearate.
What is the FDA regulatory status of etonogestrel and ethinyl estradiol vaginal rings?
NuvaRing is FDA-approved for the prevention of pregnancy in females of reproductive potential. It is a monthly vaginal ring used for three weeks, followed by a one-week ring-free interval (FDA, 2021a).
The product is regulated through an NDA and generic versions through the ANDA pathway. Generic applicants must demonstrate pharmaceutical equivalence and bioequivalence, including comparable release of both hormones. The product does not qualify for the biosimilar pathway because it is a synthetic small-molecule drug, not a biologic.
| Product |
Active ingredients |
U.S. regulatory pathway |
Manufacturer or applicant |
Status |
| NuvaRing |
Etonogestrel 11.7 mg; ethinyl estradiol 2.7 mg |
NDA |
Organon |
Approved |
| EluRyng |
Same active ingredients and strength |
ANDA |
Amneal Pharmaceuticals |
Approved |
| Generic equivalents |
Same active ingredients, strength, dosage form and route |
ANDA |
Multiple applicants |
Approved or marketed depending on applicant |
EluRyng is an FDA-approved generic equivalent of NuvaRing. FDA approved EluRyng in 2019 (FDA, 2019). The approval established that the product category had moved into a conventional generic competition phase.
What excipients are used in etonogestrel and ethinyl estradiol vaginal rings?
The reference ring uses ethylene-vinyl acetate copolymers as the structural and drug-release matrix. Magnesium stearate is used as an inactive processing or formulation component. The product has an outer diameter of approximately 54 mm and a cross-sectional diameter of approximately 4 mm (FDA, 2021a).
Excipient functions
| Excipient or material |
Primary function |
Commercial relevance |
| Ethylene-vinyl acetate copolymer |
Ring matrix, structural support and drug-release control |
Determines diffusion, flexibility and manufacturing yield |
| Magnesium stearate |
Lubrication and processing aid |
Can affect powder handling, dispersion and release |
| Primary packaging materials |
Protection from moisture, heat and handling |
Influences shelf life, patient acceptance and distribution cost |
The active ingredients are dispersed within the polymeric ring. The polymer grade, vinyl acetate content, molecular weight, processing temperature and active-particle distribution affect release kinetics. These parameters can be more important than the nominal excipient identity.
How should an excipient strategy be designed for a generic vaginal ring?
A commercially viable excipient strategy should prioritize release equivalence, mechanical performance and manufacturing reproducibility. Substituting excipients solely to reduce cost can create regulatory and litigation risk if the substitution changes release behavior or product performance.
1. Match polymer chemistry before optimizing cost
Ethylene-vinyl acetate is the lowest-risk starting material because it is associated with the reference product and has established use in controlled-release vaginal rings. A generic developer can evaluate different vinyl acetate grades, but the selected material must produce a comparable release profile for both hormones.
Higher vinyl acetate content generally increases polymer flexibility and can alter drug diffusion. Molecular weight and melt-flow properties affect extrusion, ring formation and content uniformity. A polymer that is too rigid can create insertion and removal problems. A polymer that is too soft can deform during packaging or use.
2. Control hormone dispersion
Etonogestrel and ethinyl estradiol have different physicochemical properties and release rates. Uniform dispersion is necessary to prevent initial release spikes, low-dose sections of the ring or hormone-rich regions that create batch variability.
Critical process controls include:
- Particle-size distribution for both hormones.
- Mixing time and shear.
- Polymer melt temperature.
- Residence time during extrusion or molding.
- Ring cutting, welding or joining conditions.
- Drug loading uniformity along the ring.
The analytical package should measure total drug content and release of each hormone separately. A single combined assay is insufficient to characterize performance.
3. Preserve ring mechanics
The ring must remain flexible during insertion, storage and wear. Compression force, recovery, tensile strength and dimensional stability are practical quality attributes. A formulation that meets dissolution specifications but fractures, permanently deforms or becomes uncomfortable has limited commercial value.
4. Evaluate alternative lubricants cautiously
Magnesium stearate is familiar and inexpensive. Alternative lubricants or processing aids may improve extrusion, but they can change surface characteristics, drug dispersion and release. Novel excipients would increase regulatory complexity and could require additional safety justification.
5. Treat packaging as part of the excipient and stability strategy
The product is supplied in a sealed pouch. Packaging must protect the ring from heat, moisture, oxygen and mechanical compression. A lower-cost pouch can reduce the product’s commercial advantage if it shortens shelf life or causes ring deformation during distribution.
What patents protect NuvaRing and generic etonogestrel vaginal rings?
The principal U.S. patent risk for NuvaRing arose from patents covering the hormone-releasing vaginal ring and related delivery technology. Public Orange Book records and patent litigation records identified U.S. Patent No. 5,989,581 among the key listed patents associated with NuvaRing (FDA, 2024; Organon USA Inc. v. Teva Pharmaceuticals USA, Inc., 2018).
| Patent |
General subject matter |
Relevance to generic entry |
Status |
| U.S. Patent No. 5,989,581 |
Hormone-releasing vaginal ring technology |
Central patent in NuvaRing ANDA litigation |
Expired |
| Other historical ring patents |
Vaginal delivery systems, polymer matrices and contraceptive formulations |
Potentially relevant depending on claim scope and jurisdiction |
Many expired or limited in practical effect |
Patent protection should be assessed claim by claim. A patent directed to a broad vaginal ring may be less commercially significant after expiration, while later patents directed to a specific formulation, packaging configuration or manufacturing process may still matter in selected markets.
The commercial patent estate is weaker than that of a new chemical entity because the active ingredients, dosage form and principal release concept are established. The remaining barriers are more likely to involve formulation know-how, process controls, regulatory data and manufacturing scale than basic composition-of-matter claims.
When did NuvaRing lose U.S. exclusivity?
The key U.S. NuvaRing patent expired in the late 2010s. FDA approved the first major generic competitor, EluRyng, in 2019 (FDA, 2019). NuvaRing therefore no longer has meaningful U.S. market exclusivity based on the original ring patent.
| Milestone |
Approximate timing |
| NuvaRing U.S. approval |
2001 |
| Core patent expiration period |
2018 |
| First major generic approval |
2019 |
| Current U.S. market structure |
Reference product plus generic competition |
FDA regulatory exclusivity and patent exclusivity are separate. The original approval did not create a current barrier comparable to six-month new chemical entity exclusivity or twelve-year biologic exclusivity. No biosimilar exclusivity framework applies.
Were there Paragraph IV challenges to NuvaRing?
Yes. Generic applicants challenged NuvaRing patents through ANDA Paragraph IV certifications, leading to patent litigation involving Organon and generic manufacturers. Organon brought patent litigation against Teva concerning NuvaRing-related patent rights before generic approval and launch (Organon USA Inc. v. Teva Pharmaceuticals USA, Inc., 2018).
The litigation and subsequent generic approvals show that the key entry route was an ANDA with patent certification rather than a new NDA. Once the principal patent barrier was removed or resolved, generic entry became feasible without reproducing every element of the reference product’s commercial packaging or brand positioning.
What formulation patents protect etonogestrel vaginal rings?
Formulation protection may cover:
- Ethylene-vinyl acetate polymer composition.
- Drug loading and concentration gradients.
- Release rates for etonogestrel and ethinyl estradiol.
- Ring dimensions and multilayer structures.
- Methods for incorporating steroid hormones into the polymer.
- Storage and packaging configurations.
- Specific treatment schedules or contraceptive uses.
Method-of-use patents are generally less valuable for a generic ring when the proposed label uses the same contraceptive indication as the reference product. A generic applicant may seek a section viii statement to carve out a patented use, but the commercial value of such a strategy depends on the scope of the label and the remaining claims.
The strongest practical protection may not be an active patent. Manufacturing know-how involving extrusion, active dispersion and release testing can create meaningful barriers to entry even when the patent estate is expired.
How strong is the patent estate for etonogestrel and ethinyl estradiol vaginal rings?
The U.S. patent estate is weak to moderate from an originator-defense perspective and moderate from a technical manufacturing perspective.
| Risk category |
Assessment |
Reason |
| Active ingredient patents |
Low |
Both hormones are established generic substances |
| Core ring technology |
Low to moderate |
Principal protection has expired |
| Formulation patents |
Moderate |
Claims may cover specific polymer and release designs |
| Manufacturing patents |
Moderate |
Process parameters can be difficult to replicate |
| Packaging patents |
Low to moderate |
Usually narrow and commercially avoidable |
| Regulatory barrier |
Moderate |
Dual-hormone release equivalence is technically demanding |
| Biosimilar risk |
Not applicable |
Product is a small-molecule drug |
A developer should not assume that patent expiration eliminates all freedom-to-operate concerns. The relevant review must include U.S. patents, pending applications, continuation claims and foreign rights in each intended market.
What commercial opportunities exist for excipient suppliers and manufacturers?
The highest-value opportunity is a reliable, cost-efficient ring platform rather than a novel excipient alone.
Generic and private-label supply
Health plans, pharmacy benefit managers and public contraceptive programs create demand for lower-cost generic rings. Private-label supply can also appeal to telehealth contraceptive providers and integrated reproductive-health platforms.
Improved storage and packaging
A pouch with lower material cost, better barrier properties or improved opening design can reduce distribution losses and improve patient usability. Packaging changes must preserve stability and avoid creating a separate patent or regulatory issue.
Longer-duration or simplified-use products
A ring designed for extended use could differentiate itself from the monthly schedule. This opportunity is technically attractive but requires new clinical, pharmacokinetic and regulatory support. It may also encounter method-of-use patents or require a separate NDA rather than a straightforward ANDA.
Non-hormonal or lower-dose variants
A lower-dose formulation could target users concerned about estrogen exposure. The product would not be substitutable for NuvaRing unless it met the same strength and labeling requirements, so the regulatory and commercial path would differ.
International markets
European and other international markets can support generic vaginal rings, but approval requirements, reference-product status, patent terms and reimbursement policies differ. A formulation platform that supports multiple ring diameters, hormone loads or release rates may create licensing and contract-manufacturing opportunities.
What generic launch risks exist for this vaginal ring?
The primary risks are technical and commercial rather than basic patent infringement.
- Inability to match release of both hormones over the full use period.
- Inconsistent active distribution along the ring.
- Ring fracture or deformation during manufacturing or use.
- Stability loss under temperature excursions.
- Manufacturing yield below commercial targets.
- Limited payer willingness to switch from low-cost generic competitors.
- FDA deficiencies involving dissolution, content uniformity or container-closure performance.
- Foreign patent rights that remain active after U.S. expiration.
The generic launch scenario is most favorable for a manufacturer with established polymer processing, controlled-release testing and hormonal product capabilities. A conventional tablet manufacturer without extrusion or ring-production experience faces a higher development burden.
How does the opportunity compare with ANNOVERA?
ANNOVERA is not an etonogestrel and ethinyl estradiol ring. It contains segesterone acetate and ethinyl estradiol and is designed for repeated annual use with periodic removal (FDA, 2021b).
| Attribute |
NuvaRing and generic equivalents |
ANNOVERA |
| Progestin |
Etonogestrel |
Segesterone acetate |
| Estrogen |
Ethinyl estradiol |
Ethinyl estradiol |
| Intended use |
Monthly ring cycle |
Reusable for up to one year |
| Regulatory pathway for competitors |
ANDA possible for equivalent product |
More complex, depending on product design |
| Patent and device exposure |
Mature and largely expired in the U.S. |
Potentially stronger due to reusable ring and formulation claims |
| Commercial strategy |
Cost, access and supply reliability |
Differentiation through duration and reusable design |
ANNOVERA demonstrates that duration of use and ring reusability can create more defensible commercial positioning than a direct monthly generic. It also illustrates the added technical and regulatory burden of a differentiated vaginal ring.
Key Takeaways
- The reference product contains etonogestrel, ethinyl estradiol, ethylene-vinyl acetate copolymers and magnesium stearate.
- The central commercial challenge is matching dual-hormone release, not identifying a novel excipient.
- NuvaRing’s core U.S. patent protection expired in the late 2010s, and FDA approved generic competition in 2019.
- Paragraph IV litigation affected generic entry, but the U.S. market is now primarily a generic-competition market.
- Excipient changes should focus on polymer grade, drug dispersion, mechanical properties and release control.
- The strongest non-patent barriers are manufacturing know-how, analytical capability and process yield.
- Commercial opportunities include generic supply, private-label distribution, packaging optimization and differentiated extended-use rings.
- ANNOVERA is a separate product with a different progestin and a stronger differentiation model based on annual reuse.
- Biosimilar risk does not apply because etonogestrel and ethinyl estradiol vaginal rings are synthetic small-molecule drug products.
FAQs
What is the main excipient in NuvaRing?
Ethylene-vinyl acetate copolymer is the principal structural and release-controlling material. Magnesium stearate is also identified as an inactive ingredient in product information.
Can a generic vaginal ring use a different polymer?
A generic applicant may use a different polymer composition if the product meets applicable pharmaceutical equivalence, bioequivalence, quality and performance requirements. A different polymer can create substantial development risk because it may change hormone release and flexibility.
Is etonogestrel and ethinyl estradiol vaginal ring subject to biosimilar competition?
No. Biosimilars apply to biological products. This vaginal ring is a synthetic small-molecule combination drug and is subject to the ANDA generic pathway.
What is the main regulatory test for a generic NuvaRing?
The principal test is bioequivalence and pharmaceutical equivalence, including comparable release and exposure for both etonogestrel and ethinyl estradiol. Product quality, content uniformity, stability and mechanical performance are also critical.
Can a longer-lasting etonogestrel vaginal ring use the ANDA pathway?
Only if it meets the statutory requirements for sameness in active ingredients, dosage form, route, strength and other relevant characteristics. A materially different duration, formulation or dosing schedule may require a separate NDA rather than an ANDA.
References
- U.S. Food and Drug Administration. (2019). FDA approves first generic version of NuvaRing.
- U.S. Food and Drug Administration. (2021a). NuvaRing prescribing information. Organon.
- U.S. Food and Drug Administration. (2021b). ANNOVERA prescribing information. TherapeuticsMD.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- Organon USA Inc. v. Teva Pharmaceuticals USA, Inc., patent litigation concerning NuvaRing-related ANDA certifications, U.S. District Court for the District of New Jersey (2018).
